Insider TradingJun 2, 2026, 09:46 AM
MAIA Biotechnology CEO & Director Increase Share Ownership
AI Summary
MAIA Biotechnology, Inc. announced that its founder and CEO, Vlad Vitoc, M.D., and Director Stan V. Smith, Ph.D., increased their ownership positions through open market purchases. Dr. Vitoc acquired approximately 72,700 shares at an average price of $1.3877, while Dr. Smith purchased approximately 75,000 shares at an average price of $1.336. These investments reflect strong confidence in the company's telomere-targeting immuno-oncology platform and the ateganosine program, which is advancing toward later-stage development for non-small cell lung cancer. Directors and officers now collectively hold a 20.46% stake in MAIA.
Key Highlights
- MAIA CEO Vlad Vitoc purchased 72,700 shares of common stock at an average price of $1.3877.
- Director Stan V. Smith purchased 75,000 shares of common stock at an average price of $1.336.
- The purchases underscore strong confidence in MAIA's telomere-targeting immuno-oncology platform.
- Directors and officers of MAIA now hold a 20.46% stake in the Company.
- Management believes ateganosine could become an important new standard of care for advanced non-small cell lung cancer.
Price Impact
More from MAIA